GlassScriptPhysician profile
Deborah A Spiers
NPI 1093943144
$2,164.21
in general payments reported to CMS, 2019-2025
25 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.12 · 2020: $69.35 · 2021: $247 · 2022: $368 · 2023: $1,154 · 2024: $62.02 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.63 |
| Education | $287.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $346.72 | 2023 | Veozah |
| Hologic Sales and Service, LLC | $251.48 | 2022-2024 | Novasure, Coolseal Generator, Omni Hysteroscope |
| Aspira Women'S Health INC | $179.91 | 2020-2023 | Ova1 |
| Myriad Women'S Health, INC. | $169.43 | 2023 | Myrisk |
| Abbvie INC. | $164.20 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $149.55 | 2021-2023 | |
| Agile Therapeutics, INC. | $135.78 | 2021-2023 | Twirla |
| Daiichi Sankyo INC. | $119.84 | 2020-2023 | Injectafer |
| Organon LLC | $84.46 | 2022-2025 | Nexplanon, Jada System |
| Therapeuticsmd, INC. | $77.62 | 2020-2022 | |
| Medtronic, INC. | $73.73 | 2021-2023 | Truclear |
| Bayer Healthcare Pharmaceuticals INC. | $64.83 | 2025 | |
| Biogen, INC. | $55.12 | 2025 | Zurzuvae |
| Ethicon US, LLC | $46.39 | 2023-2025 | Stratafix, Enseal, Vistaseal |
| Avion Pharmaceuticals | $41.20 | 2022-2023 | Balcoltra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $30.98 | 2025 | Slynd |
| Millicent US INC | $24.50 | 2024 | Intrarosa |
| Dexcom, INC. | $24.22 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $21.72 | 2023 | Myfembree |
| Merck Sharp & Dohme LLC | $19.77 | 2019 | |
| Evofem Biosciences, INC. | $19.46 | 2022 | |
| Scynexis, INC. | $19.29 | 2022 | |
| Shield Therapeutics INC | $19.28 | 2022 | |
| Radiometer America, INC | $16.73 | 2022 | |
| Allotrope Medical, INC | $8.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Spiers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.